Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021

por Maeda, Hideki, Uchida, Marika, Kusano, Mikiko, Tsukamoto, Katsura, Yamanoi, Moeka
Publicado 2022

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study

por Usuki, Kensuke, Sakura, Toru, Kobayashi, Yukio, Miyamoto, Toshihiro, Iida, Hiroatsu, Morita, Satoshi, Bahceci, Erkut, Kaneko, Masahito, Kusano, Mikiko, Yamada, Shunsuke, Takeshita, Shigeru, Miyawaki, Shuichi, Naoe, Tomoki
Publicado 2018

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

por Hosono, Naoko, Yokoyama, Hisayuki, Aotsuka, Nobuyuki, Ando, Kiyoshi, Iida, Hiroatsu, Ishikawa, Takayuki, Usuki, Kensuke, Onozawa, Masahiro, Kizaki, Masahiro, Kubo, Kohmei, Kuroda, Junya, Kobayashi, Yukio, Shimizu, Takayuki, Chiba, Shigeru, Nara, Miho, Hata, Tomoko, Hidaka, Michihiro, Fujiwara, Shin-Ichiro, Maeda, Yoshinobu, Morita, Yasuyoshi, Kusano, Mikiko, Lu, Qiaoyang, Miyawaki, Shuichi, Berrak, Erhan, Hasabou, Nahla, Naoe, Tomoki
Publicado 2021